ACIU – ac immune sa (US:NASDAQ)
Stock Stats
News
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome [Yahoo! Finance]
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
Down's Syndrome Market to Exhibit Growth at a CAGR of 3.81% by 2034 | DelveInsight [Yahoo! Finance]
AC Immune's stock jumps after Parkinson's therapy shows signs of benefit [Yahoo! Finance]
AC Immune SA (NASDAQ: ACIU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Form 6-K AC Immune SA For: Dec 18
Form SC 13G/A AC Immune SA Filed by: AFFIRIS AG in Liqu
Form 6-K AC Immune SA For: Dec 10
Form SC 13G/A AC Immune SA Filed by: BIOTECHNOLOGY VALUE FUND L P
Form 6-K AC Immune SA For: Nov 14
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.